These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Addition of monofluorophosphate to estrogen therapy in postmenopausal osteoporosis: a randomized controlled trial. Reid IR; Cundy T; Grey AB; Horne A; Clearwater J; Ames R; Orr-Walker BJ; Wu F; Evans MC; Gamble GD; King A J Clin Endocrinol Metab; 2007 Jul; 92(7):2446-52. PubMed ID: 17440020 [TBL] [Abstract][Full Text] [Related]
23. High bone turnover is associated with low bone mass and spinal fracture in postmenopausal women. Ravn P; Rix M; Andreassen H; Clemmesen B; Bidstrup M; Gunnes M Calcif Tissue Int; 1997 Mar; 60(3):255-60. PubMed ID: 9069162 [TBL] [Abstract][Full Text] [Related]
24. Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. Haguenauer D; Welch V; Shea B; Tugwell P; Adachi JD; Wells G Osteoporos Int; 2000; 11(9):727-38. PubMed ID: 11148800 [TBL] [Abstract][Full Text] [Related]
25. Aging bone and osteoporosis: strategies for preventing fractures in the elderly. Ettinger MP Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222 [TBL] [Abstract][Full Text] [Related]
26. The value of osteopontin in the assessment of bone mineral density status in postmenopausal women. Fodor D; Bondor C; Albu A; Simon SP; Craciun A; Muntean L J Investig Med; 2013 Jan; 61(1):15-21. PubMed ID: 23117696 [TBL] [Abstract][Full Text] [Related]
27. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. Hochberg MC; Greenspan S; Wasnich RD; Miller P; Thompson DE; Ross PD J Clin Endocrinol Metab; 2002 Apr; 87(4):1586-92. PubMed ID: 11932287 [TBL] [Abstract][Full Text] [Related]
28. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis. McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386 [TBL] [Abstract][Full Text] [Related]
29. Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia). Fujiwara S; Hamaya E; Sato M; Graham-Clarke P; Flynn JA; Burge R Clin Interv Aging; 2014; 9():1879-93. PubMed ID: 25395843 [TBL] [Abstract][Full Text] [Related]
30. [Effects of the combined raloxifene-sodium fluoride therapy on bone mass and bone turnover in women with postmenopausal osteoporosis]. Celi M; Letizia C; Ragno A; Minisola S; D'Erasmo E; Mazzuoli GF Minerva Med; 2002 Dec; 93(6):471-8. PubMed ID: 12515970 [TBL] [Abstract][Full Text] [Related]
31. Vertebral fracture in postmenopausal Chinese women: a population-based study. Cui L; Chen L; Xia W; Jiang Y; Cui L; Huang W; Wang W; Wang X; Pei Y; Zheng X; Wang Q; Ning Z; Li M; Wang O; Xing X; Lin Q; Yu W; Weng X; Xu L; Cummings SR Osteoporos Int; 2017 Sep; 28(9):2583-2590. PubMed ID: 28560474 [TBL] [Abstract][Full Text] [Related]
32. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. Cummings SR; Black DM; Thompson DE; Applegate WB; Barrett-Connor E; Musliner TA; Palermo L; Prineas R; Rubin SM; Scott JC; Vogt T; Wallace R; Yates AJ; LaCroix AZ JAMA; 1998 Dec 23-30; 280(24):2077-82. PubMed ID: 9875874 [TBL] [Abstract][Full Text] [Related]
34. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Greenspan SL; Bone HG; Ettinger MP; Hanley DA; Lindsay R; Zanchetta JR; Blosch CM; Mathisen AL; Morris SA; Marriott TB; Ann Intern Med; 2007 Mar; 146(5):326-39. PubMed ID: 17339618 [TBL] [Abstract][Full Text] [Related]
35. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C; JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157 [TBL] [Abstract][Full Text] [Related]
36. Slow-release sodium fluoride in the management of postmenopausal osteoporosis. A randomized controlled trial. Pak CY; Sakhaee K; Piziak V; Peterson RD; Breslau NA; Boyd P; Poindexter JR; Herzog J; Heard-Sakhaee A; Haynes S; Adams-Huet B; Reisch JS Ann Intern Med; 1994 Apr; 120(8):625-32. PubMed ID: 8135445 [TBL] [Abstract][Full Text] [Related]
38. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Cummings SR; Karpf DB; Harris F; Genant HK; Ensrud K; LaCroix AZ; Black DM Am J Med; 2002 Mar; 112(4):281-9. PubMed ID: 11893367 [TBL] [Abstract][Full Text] [Related]
39. Present and future of osteoporosis therapy. Seeman E; Tsalamandris C; Bass S; Pearce G Bone; 1995 Aug; 17(2 Suppl):23S-29S. PubMed ID: 8579894 [TBL] [Abstract][Full Text] [Related]
40. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy. Ste-Marie LG; Schwartz SL; Hossain A; Desaiah D; Gaich GA J Bone Miner Res; 2006 Feb; 21(2):283-91. PubMed ID: 16418784 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]